Yoshimasa Miyagawa - Concepedia

Author

Yoshimasa Miyagawa

Hyogo Medical University

Also Known As

YOSHIMASA MIYAGAWA, Yoshimasa Miyagawa

Publications

598

Citations

H-Index

Concepts

All Affiliations

Hyogo Medical University Tokushima Breast Care Clinic Naga Municipal Hospital Tokushima University Kansai Rosai Hospital

About

Yoshimasa Miyagawa is an author at Hyogo Medical University specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	248
2	Cell Biology	4	4	101
3	Health Sciences	3	3	40
4	Immunology	2	2	52
5	Endocrinology	1	1	14

Yoshimasa Miyagawa

Publications

536

Citations

H-Index

Page 1

	Year	Citations
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel Kazuhiro Araki, Yoshinori Ito, Ippei Fukada, BMC Cancer	2018	55
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, Clinical Breast Cancer	2018	51
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer Arisa Nishimukai, Tomoko Yagi, Ayako Yanai, Clinical Breast Cancer Breast OncologyEndocrine-related CancerMedicinePathologyGynecology	2014	48
Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes Tomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa, The Breast	2016	46
Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine Michiko Imamura, Takashi Morimoto, Chiyomi Egawa, Scientific Reports	2019	33
Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2− Breast Cancer Ayako Yanai, Natsuko Inoue, Tomoko Yagi, Clinical Breast Cancer Breast OncologyHigh Ki-67MedicineReceptor Tyrosine KinaseBreast Cancer	2014	32
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers Yukie Fujimoto, Takahiro Watanabe, Akira I. Hida, Breast Cancer Breast OncologyKi67 Expression LevelsMedicineImmunologyBreast Cancer	2019	32
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes Michiko Imamura, Takashi Morimoto, Takashi Nomura, World Journal of Surgical Oncology	2018	28
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers Yukie Enomoto, Takashi Morimoto, Arisa Nishimukai, International Journal of Clinical Oncology Surgical OncologyResidual Breast CancersBreast OncologyMedicinePathology	2015	25
Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers Tomoko Yagi, Natsuko Inoue, Ayako Yanai, Breast Cancer Breast OncologyGeminin Expression LevelsMedicineCancer GenomicsKi67-high Subset	2014	22

Page 1